Nurix Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
04 janv. 2023 07h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics Announces Clearance of Investigational New Drug Application for NX-5948 Supporting Plans to Expand Enrollment to U.S. Clinical Sites
15 déc. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
NX-5948 is being evaluated in patients with relapsed and refractory B-cell malignancies Phase 1 clinical trial now enrolling patients in the United Kingdom with plans to expand to clinical sites in...
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting
12 déc. 2022 17h30 HE
|
Nurix Therapeutics, Inc.
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK...
Nurix Therapeutics Announces Webcast to Review Data from its Phase 1 Clinical Trial of BTK Degrader, NX-2127, Presented at the 64th American Society of Hematology Annual Meeting
07 déc. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Announces DeTIL-0255 Scientific Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) and Successful Completion of DeTIL-0255 Phase 1 Safety Run-in
10 nov. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Announces Initial NX-1607 Phase 1 Data Presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Demonstrating Targeted CBL-B Inhibition in Patients with Advanced Malignancies
10 nov. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
Biomarker results are a positive demonstration of target engagement for this first-in-class CBL-B inhibitor Biomarker levels achieved with NX-1607 treatment correspond to levels associated with...
Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
03 nov. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...
Nurix Therapeutics to Participate in Upcoming Investor Conferences
02 nov. 2022 16h01 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with...
Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit
26 oct. 2022 07h00 HE
|
Nurix Therapeutics, Inc.
Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved by day 8 and...
Nurix Therapeutics Announces Presentations at the 5th Annual Targeted Protein Degradation (TPD) Summit
19 oct. 2022 09h00 HE
|
Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced...